KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Notes Payables: 2009-2022

Historic Notes Payables for Novavax (NVAX) over the last 8 years, with Dec 2022 value amounting to $324.9 million.

  • Novavax's Notes Payables was N/A to $324.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $324.9 million, marking a year-over-year change of. This contributed to the annual value of $324.9 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q4 2022, Novavax's Notes Payables is $324.9 million, which was up 0.11% from $324.5 million recorded in Q3 2022.
  • Over the past 5 years, Novavax's Notes Payables peaked at $324.9 million during Q4 2022, and registered a low of $323.8 million during Q1 2022.
  • For the 1-year period, Novavax's Notes Payables averaged around $324.3 million, with its median value being $324.3 million (2022).